• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

June 5, 2013

View Archived Issues

Not So 'Fost'? Rigel RA Drug Could Survive AstraZeneca Hit

Although efficacy below AstraZeneca plc's standard caused the pharma firm to give up rights to fostamatinib, the spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis (RA) met important endpoints, and Rigel Pharmaceuticals Inc. could find another partner and explore new diseases with it. Read More

Morphosys, GSK Ink $586M Pact for MOR103 in RA, MS

German biotech received a badly needed boost this week with the news that GlaxoSmithKline plc was in-licensing MOR103, an antibody in clinical development in rheumatoid arthritis (RA) and multiple sclerosis (MS) at veteran antibody developer Morphosys AG, in return for an up-front payment of €22.5 million (US$29 million), plus another potential €423 million in milestones linked to its progress through clinical development, regulatory approval and sales. Read More

Obama: It's Time to Stop the Patent Trolls

The president is getting gruff with patent trolls, using his executive powers to waylay their frivolous lawsuits and urging Congress to pass legislation that would make trolling far less appetizing. Read More

Akebia's $41M Cash Infusion Boosts Anemia Drug Work

A bit more than a year after handing in positive results in a Phase II study for AKB-6548 in chronic kidney disease (CKD), Akebia Therapeutics Inc., of Cincinnati, secured a $41 million Series C financing to fund ongoing development of the drug. Read More

FDA Clinical Hold on PLX Safety Study Trips Pluristem

Shares of Pluristem Therapeutics Inc. stumbled Tuesday on word that the FDA placed a clinical hold on the U.S. Phase II study (IND 15038) of its allogeneic cell therapy in intermittent claudication (IC), a subset of peripheral artery disease (PAD), following a serious allergic reaction that required the patient's hospitalization. Read More

China Biologics Executives See a Better Way Forward

BEIJING – As manufacturers of biologics reflect on the price of foreign products in China, they say there must be a better way. Read More

Stock Movers

Read More

Other News To Note

• BrainStorm Cell Therapeutics Inc., of New York, received the third installment of a 2013 grant from Israel's Office of the Chief Scientist for $335,000. Read More

Clinic Roundup

• KemPharm Inc., of North Liberty, Iowa, presented data at the International Conference on Opioids in Boston showing that the firm's pain drug candidate, KP201, has abuse-deterrent properties and has been shown to significantly limit narcotic exposure upon intranasal administration and intravenous injection. Read More

ASCO Roundup

• Ambit Biosciences Corp., of San Diego, presented data from its Phase II ACE study of quizartinib (AC220), a FLT3 inhibitor, including data from 176 patients with either relapsed acute myeloid leukemia (AML) or AML that was refractory to second-line chemotherapy or hematopoietic stem cell transplantation (HSCT). Read More

Pharma: Other News To Note

• Bristol-Myers Squibb Co., of Princeton, N.J., and AstraZeneca plc, of London, said the FDA accepted for review and granted priority designation for the biologics license application for metreleptin in metabolic disorders associated with inherited or acquired lipodsytrophy. Read More

Pharma: Clinic Roundup

• CSL Behring, of King of Prussia, Pa., dosed the first patient in Part 3 of its AFFINITY trial program. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 11, 2025.
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • AI-generated illustration of heart and metabolic impact

    Deep Apple signs big Novo deal for cardiometabolic small molecules

    BioWorld
    Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
  • Philochem, BMS ink $1.35B deal for prostate cancer candidate OncoACp3

    BioWorld
    Philochem AG’s ligand-targeting approach drew to the table Bristol Myers Squibb Co. in a potential $1.35 billion agreement granting BMS subsidiary Rayzebio Inc....
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe